Figure 2
From: Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma
Kaplan–Meier survival analysis for overall survival of the entire patient cohort Kaplan–Meier survival analysis for overall survival of the entire patient cohort (A). Median OS in patients with presence of ITGB1 was 22.5 months (95% confidence interval (95% CI) 15.3–29.7 months), and 34.1 months (95% CI 25.3–42.4 months, P = 0.024) without ITGB1 expression. Median OS in patients after primary surgery (B) with ITGB1 expression in the tumor was 10.2 months (95% CI 1.9–41.7 months) compared to 31.4 months (95% CI 21.1–144.2 months, P = 0.008) in the group without ITGB1 expression. Patients that received neoadjuvant treatment before surgery (C) showed a median OS with ITGB1 expression of 22.7 months (95%CI 15.3–30.2 months) vs. 25.9 months without ITGB1 expression (95% CI 20.6–31.2 months), P = 0.423).
